Login
$TRVI
$13.29 -$0.36 (2.64%) Live

$TRVI 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting

06 Aug 2026 8-K: Results of Operations and Financial Condition

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026

04 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

(Pursuant to Section 242 of theGeneral Corporation Law of the State of Delaware)

05 May 2026 8-K: Results of Operations and Financial Condition

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement

17 Apr 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with Morgan Stanley & Co. LLC (“Morgan Stanley”) and Leerink Partners LLC (“Leerink Partners”), and each of the other Underwriters named in Schedule...

17 Mar 2026 8-K: Results of Operations and Financial Condition

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough

09 Mar 2026 8-K: Other Events

On March 9, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced results of the Company’s End-of-Phase 2 meeting with the U.S. Food and Drug Administration (the “FDA”). At the meeting, the Company gained over...

05 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 4, 2025, Trevi Therapeutics, Inc. (the “Company”) announced the hiring of David Hastings to serve as the Company’s Chief Financial Officer and principal financial officer, effective January 6, 2026.

13 Nov 2025 8-K: Results of Operations and Financial Condition

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026

20 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

On August 14, 2025, Trevi Therapeutics, Inc. (the “Company”) and Lisa Delfini, the Company’s Chief Financial Officer, agreed that her employment with the Company would end on August 22, 2025 (the “Effective Date”) and that she would resi...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF

17 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

On June 11, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders, upon the recommendation of the Bo...

04 Jun 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with Morgan Stanley & Co. LLC (“Morgan Stanley”), Leerink Partners LLC (“Leerink Partners”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and...

02 Jun 2025 8-K: Other Events

On June 2, 2025, Trevi Therapeutics, Inc. (the “Company”) notified Leerink Partners LLC (“Leerink Partners”) that it was terminating the prospectus, dated August 15, 2023 (the “ATM Prospectus”), related to the sales agreement (the “Sales...

02 Jun 2025 8-K: Other Events

On June 2, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced positive topline results from its Phase 2b CORAL clinical trial of Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients w...

08 May 2025 8-K: Results of Operations and Financial Condition

Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025

18 Mar 2025 8-K: Results of Operations and Financial Condition

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonar...

10 Mar 2025 8-K: Other Events

On March 10, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced positive topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with refractory chronic cough (“RCC”) (N=66). ...

08 Jan 2025 8-K: Results of Operations and Financial Condition; Other Events

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

16 Dec 2024 8-K: Entry into a Material Definitive Agreement; Other Events

Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink Partners”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and Oppenheimer & Co. Inc. (“Oppenheimer”), and ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support